Inflammatory nail conditions. Part 1: nail changes in psoriasis.
Administration, Topical
Dermatologic Agents
/ administration & dosage
Dermoscopy
Glucocorticoids
/ administration & dosage
Humans
Injections, Intralesional
Methotrexate
/ therapeutic use
Nail Diseases
/ diagnosis
Nails
/ pathology
Psoriasis
/ complications
Steroids
/ administration & dosage
Triamcinolone
/ administration & dosage
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
27
05
2020
accepted:
29
05
2020
pubmed:
22
11
2020
medline:
22
9
2021
entrez:
21
11
2020
Statut:
ppublish
Résumé
Nail changes are visible in a variety of inflammatory dermatoses. The commonest dermatological condition with nail manifestations is chronic plaque psoriasis. This two-part article reviews the nail signs in psoriasis in Part 1, and the nail changes in cutaneous lichen planus and alopecia areata in Part 2. It provides a brief summary of the salient points in the clinical features, management and prognosis of these entities, with practical recommendations that may be beneficial to all dermatologists.
Substances chimiques
Dermatologic Agents
0
Glucocorticoids
0
Steroids
0
Triamcinolone
1ZK20VI6TY
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-15Informations de copyright
© 2020 British Association of Dermatologists.
Références
de Berber DAR, Baran R. Science of the nail apparatus. In: Baran and Dawber’s Diseases of the Nails and their Management, 4th edn (Baran R, de Berker DAR, Holzberg M, Thomas L eds). Oxford: Blackwell Science Ltd, 2012; 1-50.
Manhart R, Rich P. Nail psoriasis. Clin Exp Rheumatol 2015; 33: S7-13.
Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis 2017; 7: 51-63.
Dehesa L, Tosti A. Treatment of inflammatory nail disorders. Dermatol Ther 2012; 25: 525-34.
Haneke E. Non-infectious inflammatory disorders of the nail apparatus. J Dtsch Dermatol Ges 2009; 7: 787-97.
Pasch MC. Nail psoriasis: a review of treatment options. Drugs 2016; 76: 675-705.
Yorulmaz A, Artuz F. A study of dermoscopic features of nail psoriasis. Adv Dermatol Allergol 2017; 35: 28-35.
Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-12.
Rigopoulos D, Baran R, Chiheb S et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin disease: a dermatologist and nail expert group consensus. J Am Acad Dermatol 2019; 81: 228-40.
Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC. The prevalence of onychomycosis in psoriatic patients: a systemic review. J Eur Acad Dermatol Venereol 2014; 28: 533-41.
Ventura A, Mazzeo M, Gaziano R et al. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther 2017; 11: 2527-35.
Kole L, Cantrell W, Elewski B. A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone dipropionate ointment (64 mg/g) in patients with nail psoriasis. J Drugs Dermatol 2014; 13: 912-15.
De Simone C, Maiorino A, Tassone F et al. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venerol 2013; 27: 1003-6.
de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 13: 90-5.
Gumusel M, Ozdemir M, Mevlitglu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080-4.
Tosti A, Ricotti C, Romanelli P et al. Evaluation of efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-71.
Rich P, Gooderham M, Bachelez H et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016; 74: 134-42.
Merola JF, Elewski B, Tatulch S et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2017; 77: 79-87.
Luger TA, Barker J, Lambert J et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol 2009; 23: 896-904.
Thaçi D, Unnebrink K, Sundaram M et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol 2015; 29: 353-60.
Rich P, Griffiths CE, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-31.
van der Heijde D, Deodhar A, FitzGerald O et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trail of certolizumab pegol in psoriatic arthritis. RMD Open 2018; 4: e000582.
Reich K, Sullivan J, Arenberger P et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomised placebo-controlled TRANSFIGURE trial. Br J Dermatol 2019; 181: 954-66.
van de Kerkhof P, Guenther L, Gottlieb AB et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNDERCOVER-3. J Eur Acad Dermatol Venereol 2017; 31: 477-82.
Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273-86.
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318-28.
Rich P, Bourcier M, Sofen H et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol 2014; 170: 398-407.
Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405-17.
Foley P, Gordon K, Griffith CEM et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions. A secondary analysis of 2 randomized clinical trials. JAMA Dermatol 2018; 154: 676-83.
Papp KA, Blauvelt A, Bukhalo M et al. Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: analysis of scalp, palmoplantar, and nail subgroups. J Am Acad Dermatol 2017; 74: 24.